The article explores the “Femtech” industry, which focuses on innovative solutions for women’s health issues. In the Historic Inequality in Medicine paragraph, Aspivix’s solution is introduced as having finally developed a device that could impact positively women’s health. Ikram Guerd, VP of Global Marketing is also sharing her experience when pitching to investors and their initial reaction.

Read the full article at https://venturistbysvs.substack.com/p/exploring-femtech to understand the challenges, innovations, and immense potential of Femtech.

Here is a quick summary of the content of the article:
The Venturist is the in-house publication team of SVS (Strategic Venture Society) , offering a Gen Z take on tech/venture capital trends and blazing startups.

Despite addressing 50% of the population, Femtech is often considered “niche” due to historical biases in the male-dominated medical field and investment community.

Women’s health has been historically underfunded and under-researched, leading to a lack of innovation in areas like menstruation, menopause, and fertility.

This disparity is further compounded by censorship of women’s health topics and a lack of data on female-specific conditions.

While the industry faces challenges in securing funding and overcoming these biases, it’s a rapidly growing market with huge potential, projected to reach $1 trillion by 2040. The article highlights successful Femtech companies and their strategies, including data-driven approaches, business-to-business models, and end-to-end support systems.

It also discusses the impact of the overturning of Roe v. Wade, which has both increased the need for Femtech solutions and created new challenges.